Beyond Neoantigens: Antigens Derived from Tumor Drivers As Cancer Vaccine Targets

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2023 Jul 10

PMID 37428103

Authors

Erika J Crosby

Zachary C Hartman

H Kim Lyerly

Affiliations

Soon will be listed here.

Abstract

A vaccine targeting HER2, a nonmutated but overexpressed tumor antigen, readily primed T cells for ex vivo expansion and adoptive transfer with minimal toxicity. This regimen led to intramolecular epitope spreading in a majority of patients and offers a treatment modality that may improve outcomes for patients with metastatic breast cancer expressing HER2. See related article by Disis et al., p. 3362.

References

Nejo T, Matsushita H, Karasaki T, Nomura M, Saito K, Tanaka S . Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. Cancer Immunol Res. 2019; 7(7):1148-1161. DOI: 10.1158/2326-6066.CIR-18-0599. View

Royce M, Osgood C, Amatya A, Fiero M, Chang C, Ricks T . FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clin Cancer Res. 2021; 28(8):1487-1492. PMC: 9012688. DOI: 10.1158/1078-0432.CCR-21-3247. View

Crosby E, Gwin W, Blackwell K, Marcom P, Chang S, Maecker H . Vaccine-Induced Memory CD8 T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. Clin Cancer Res. 2019; 25(9):2725-2736. PMC: 6497539. DOI: 10.1158/1078-0432.CCR-18-3102. View

Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L . Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer. 2010; 10(5):392-7. DOI: 10.3816/CBC.2010.n.052. View

Disis M, Dang Y, Coveler A, Childs J, Higgins D, Liu Y . A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer. Clin Cancer Res. 2023; 29(17):3362-3371. PMC: 10754340. DOI: 10.1158/1078-0432.CCR-22-3578. View

Crosby E, Acharya C, Haddad A, Rabiola C, Lei G, Wei J . Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clin Cancer Res. 2020; 26(17):4670-4681. PMC: 7483405. DOI: 10.1158/1078-0432.CCR-20-0389. View

Rassy E, Rached L, Pistilli B . Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer. Breast. 2022; 66:217-226. PMC: 9636477. DOI: 10.1016/j.breast.2022.10.016. View

Hu Z, Li Z, Ma Z, Curtis C . Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat Genet. 2020; 52(7):701-708. PMC: 7343625. DOI: 10.1038/s41588-020-0628-z. View

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

10.

Baselga J, Cortes J, Kim S, Im S, Hegg R, Im Y . Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2011; 366(2):109-19. PMC: 5705202. DOI: 10.1056/NEJMoa1113216. View

11.

Meric-Bernstam F, Beeram M, Hamilton E, Oh D, Hanna D, Kang Y . Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022; 23(12):1558-1570. DOI: 10.1016/S1470-2045(22)00621-0. View

12.

Walens A, Lin J, Damrauer J, McKinney B, Lupo R, Newcomb R . Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. Nat Commun. 2020; 11(1):5017. PMC: 7539014. DOI: 10.1038/s41467-020-18730-z. View

13.

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View